Bain Capital Life Sciences and TCGX led a $200m Series C round in ADARx Pharmaceuticals.

Bain Capital Life Sciences, a venture capital firm for life sciences startups, and TCGX, a science-driven investment firm, led a $200m Series C round in ADARx Pharmaceuticals, a clinical stage biotechnology company, with participation from Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed and SR One. “ADARx has developed a unique siRNA platform that we believe has the potential to generate differentiated clinical data from several programs over the near and long-term. We share the Company’s commitment to targeting diseases across therapeutic areas where there is significant unmet medical need and look forward to supporting the advancement of their platform technology and growing drug development pipeline, with the ultimate goal of bringing important new treatments to patients,” Ricky Sun, Bain Capital Life Sciences Partner.